Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Healthcare — Hospitals & Diagnostics.”
₹96 Cr revenue.
COGS 26.6%, employees 7.6%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 19.3%▲ | 7.9% |
| ROCE | 23.8%▲ | 11.3% |
| Net Margin | 38.5%▲ | 9.3% |
| EBITDA Margin | 51.3%▲ | 21.9% |
| Debt To Equity | 0.00x▼ | 0.16x |
| Rev Growth 3yr | 8.4%▼ | 12.4% |
| EPS Growth 3yr | 13.9%▲ | 11.8% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹129 Cr +33.7% | ₹96 Cr +30.1% | ₹74 Cr +19.9% | ₹62 Cr -23.3% | ₹81 Cr -64.4% | ₹227 Cr +685.3% | ₹29 Cr +24.0% | ₹23 Cr |
| Other Income | ₹20 Cr +34.9% | ₹15 Cr +20.4% | ₹13 Cr +73.4% | ₹7 Cr +4.7% | ₹7 Cr +138.7% | ₹3 Cr +80.8% | ₹2 Cr +115.7% | ₹0.74 Cr |
| Total Income | ₹149 Cr +33.9% | ₹112 Cr +28.7% | ₹87 Cr +25.5% | ₹69 Cr -21.1% | ₹88 Cr -61.9% | ₹230 Cr +653.5% | ₹30 Cr +26.9% | ₹24 Cr |
| COGS | ₹36 Cr +40.2% | ₹26 Cr +17.4% | ₹22 Cr +21.9% | ₹18 Cr -43.3% | ₹32 Cr -38.7% | ₹52 Cr +288.9% | ₹13 Cr +22.4% | ₹11 Cr |
| ₹74 Cr +56.6% | ₹48 Cr +12.4% | ₹42 Cr +25.4% | ₹34 Cr -23.9% | ₹44 Cr -42.9% | ₹78 Cr +279.9% | ₹20 Cr +19.7% | ₹17 Cr | |
| Profit Before Tax | ₹75 Cr +17.0% | ₹64 Cr +44.4% | ₹44 Cr +25.6% | ₹35 Cr -18.3% | ₹43 Cr -71.6% | ₹152 Cr | ₹10 Cr +44.6% | ₹7 Cr |
| ₹17 Cr +2.4% | ₹16 Cr +33.3% | ₹12 Cr +30.5% | ₹9 Cr -15.0% | ₹11 Cr -71.1% | ₹38 Cr | ₹2 Cr +38.3% | ₹2 Cr | |
| Net Profit | ₹58 Cr +22.0% | ₹48 Cr +48.6% | ₹32 Cr +23.8% | ₹26 Cr -19.4% | ₹32 Cr -71.7% | ₹114 Cr | ₹8 Cr +46.7% | ₹5 Cr |
| Profit (Owners) | ₹57 Cr +20.5% | ₹48 Cr +45.6% | ₹33 Cr +44.4% | ₹23 Cr -19.6% | ₹28 Cr -71.7% | ₹100 Cr | ₹7 Cr +35.5% | ₹5 Cr |
| Minority Interest | ₹0.73 Cr | ₹0.04 Cr ↑ Recovery | (₹0.63 Cr) ↓ Decline | ₹3 Cr -18.2% | ₹4 Cr -71.6% | ₹14 Cr | ₹0.89 Cr +298.5% | ₹0.22 Cr |
| EPS | ₹66.91 | ₹55.52 | ₹38.14 | ₹30.19 | ₹37.56 | ₹132.91 | ₹9.06 | ₹7.83 |
| Diluted Shares | ₹0.86 Cr | ₹0.86 Cr | ₹0.86 Cr | ₹0.75 Cr | ₹0.75 Cr | ₹0.75 Cr | ₹0.75 Cr | ₹0.64 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Schedule of Analyst/ Investor Meeting
Special Window for Re-lodgement of Transfer Requests of Physical shares
Transcript of Analysts/Investors Call pertaining to the Financial Results for the third quarter and nine months ended December 31, 2025
Audio Recording of Analysts/Investors Call pertaining to the Unaudited Financial Results for the third quarter and nine months ended December 31, 2025
Letter for Updation
Intimation of Re-Scheduling of the Earning Concall under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015.
Submission of Advertisement Clipping of the extract of the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended 31st December, 2025
Investor''s Presentation
Submission of Unaudited Financial Results of the Company for the quarter and Nine Months ended December 31, 2025
Submission of Unaudited Financial Results of the Company for the Quarter and Nine Months ended December 31, 2025
3B Blackbio Dx Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve the Unaudited Standalone and .... 3B Black...
Certificate under Reg.74(5) of SEBI (DP)Regulations, 2018
Special Window for Re-lodgement of Transfer Requests of Physical Shares
Closure of Trading Window
Disclosure Under Regulation 29(2) of SEBI (SAST) Regulations, 2011
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.